RESEARCH ARTICLE

Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia

Juliette M. Bouyssou1,2*, Chia-Jen Liu1,3,4*, Mark Bustoros1*, Romanos Sklavenitis-Pistofidis1, Yosra Aljawai1, Salomon Manier1, Amir Yosef1, Antonio Sacco1, Katsutoshi Kokubun1, Shokichi Tsukamoto1, Adriana Perilla Glen1, Daisy Huynh1, Jorge J. Castillo1, Steven P. Treon1, Véronique Leblond5, Olivier Hermine6, Aldo M. Roccaro1, Irene M. Ghobrial1‡*, Marzia Capelletti1‡*

1 Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston MA, United States of America, 2 Université Paris-Saclay / Hôpital Necker-Enfants Malades, Paris, France, 3 Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, 4 School of Medicine, National Yang-Ming University, Taipei, Taiwan, 5 Department of Hematology at Pitié Salpêtrière Hospital, Paris, France, 6 INSERM UMR 1163, Laboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutic Implications, Paris, France

☯ These authors contributed equally to this work.
‡ These authors also contributed equally to this work.
* marzia_capelletti@dfci.harvard.edu (MC); irene_ghobrial@dfci.harvard.edu (IMG)

Abstract

Waldenström Macroglobulinemia (WM) is a low-grade B-cell lymphoma characterized by disease progression from IgM MGUS to asymptomatic and then symptomatic disease states. We profiled exosomes from the peripheral blood of patients with WM at different stages (30 smoldering/asymptomatic WM, 44 symptomatic WM samples and 10 healthy controls) to define their role as potential biomarkers of disease progression. In this study, we showed that circulating exosomes and their miRNA content represent unique markers of the tumor and its microenvironment. We observed similar levels of miRNAs in exosomes from patients with asymptomatic (smoldering) and symptomatic WM, suggesting that environmental and clonal changes occur in patients at early stages of disease progression before symptoms occur. Moreover, we identified a small group of miRNAs whose expression correlated directly or inversely with the disease status of patients, notably the known tumor suppressor miRNAs let-7d and the oncogene miR-21 as well as miR-192 and miR-320b. The study of these miRNAs’ specific effect in WM cells could help us gain further insights on the mechanisms underlying WM pathogenesis and reveal their potential as novel therapeutic targets for this disease.

Introduction

Waldenström Macroglobulinemia (WM) is a low-grade B-cell lymphoma that is characterized mainly by infiltration of the bone marrow with lymphoplasmacytic cells and the secretion of an immunoglobulin M (IgM) protein[1]. There are distinct stages of disease progression for
WM, starting from the precursor condition termed IgM monoclonal gammopathy of undetermined significance (IgM MGUS) that is defined by a bone marrow infiltration below 10%. IgM MGUS has a rate of progression of 1.5–2% risk of progression to WM per year[2]. Patients with smoldering/asymptomatic WM display no major symptoms and are observed until their disease progresses to symptomatic WM[3]. The later disease state is characterized by symptoms such as anemia, peripheral neuropathy or organomegaly[3]. Despite the differences in clinical presentation of these stages of the disease, the molecular mechanisms underlying WM progression largely remain to be elucidated[4–6].

Exosomes are 50–140 nm vesicles secreted by cells of different types including tumor cells[7]. They mediate intercellular communication by transporting a cargo of lipids, proteins and nucleic acids and transferring it to recipient cells[7]. It has been shown that exosomes can promote cancer progression through the regulation of various oncogenic processes including reprogramming of the tumor microenvironment, metastasis, immune escape and drug resistance[8, 9]. Interestingly, these oncogenic effects can be carried out by the miRNAs contained in these exosomes. In fact, different studies have shown that exosomal miRNAs can have prognostic and biological implications in the pathogenesis of many cancers[10–14].

MicroRNAs (miRNAs) are small, non-coding 19–22 nucleotide long RNAs that exert post-transcriptional regulation by binding the 3'UTR region and in some cases the coding region of target messenger RNAs, hence inhibiting their translation[15, 16]. Due to their ability to modulate essential cellular processes, miRNAs play an important role in tumorigenesis and their deregulation is a hallmark of cancer[17, 18]. In fact, large numbers of miRNAs have demonstrated oncogenic or tumor suppressor properties in specific cellular contexts[19, 20].

There is evidence that miRNAs are not randomly sorted but rather actively incorporated into exosomes[21]. Furthermore, it has been reported that precursor miRNAs can be processed into mature miRNAs inside tumor-derived exosomes carrying the microRNA biogenesis machinery[13]. This supports the notion that exosomal miRNAs can play an active role in recipient cells.

Exosomes can travel through body fluids to transfer their cargo and can be isolated from peripheral blood[21]. Circulating exosomes originate from various cell types including tumor cells, immune cells and cells of the tumor microenvironment. The analysis of these exosomes’ content can provide valuable information on molecular changes occurring during disease progression. A number of recent studies have identified exosomal miRNAs with a promising potential for cancer diagnosis and prognosis, including one study in patients with multiple myeloma, a hematologic malignancy biologically close to WM[22–26]. Furthermore, miRNAs from circulating exosomes display a number of advantages as prognosis markers, including their high stability thanks to the protection from nucleases conferred by the exosomal membrane and the low invasiveness of the sampling method[26]. Therefore, we sought to examine the content of the circulating exosomes of WM patients to identify specific miRNAs that are deregulated during disease progression.

Material and methods
Patient samples
Peripheral blood and bone marrow biopsy samples were collected between 2007 and 2016 from patients with WM and healthy controls after approval from the Dana-Farber Cancer Institute Institutional Review Board (IRB# 09–233) with written informed consent. No minors were included in this research. Informed consent was obtained from all patients in accordance with the Declaration of Helsinki. The patients’ disease status was determined based on the Mayo stratification of Macroglobulinemia[2]. A total of 84 samples were analyzed including 10...
healthy controls, 30 smoldering WM and 44 symptomatic WM. The mean age of the 10 healthy controls was 38 years old.

**Exosome isolation and characterization**

We used an ultracentrifugation method to isolate exosomes from plasma (2 to 10 mL). The detailed isolation procedure is shown in S1A Fig. The expected exosomes size range was confirmed by electron microscopy using antibodies directed against CD63 and CD81 as previously described and by particle size analysis with a NanoSight NS300 Instrument (Malvern instruments)[7].

**Cell lines**

The BCWM.1 and MWCL-1 cell lines were kindly gifted to us from Dr. Steven Treon (Dana Farber Cancer Institute, Harvard, MA) and Dr. Steven Ansell (Mayo Clinic, Rochester, MN). Cell lines were cultured in RPMI-1640 medium containing 10% fetal bovine serum, 2 μM L-glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin. Exosome-depleted culture medium was prepared by centrifuging the supplemented RPMI 1640 medium overnight at 100,000 x g at 4˚C then filtering through 0.22μM pore size PVDF filters (Millex). Cells were washed twice in PBS and resuspended in the freshly prepared exosome-depleted medium at a concentration of 400,000 cells per mL. After 48 hours in culture, a volume of 120 mL of cells and culture supernatant were collected for each cell line and centrifuged at 2,000 g for 10 minutes at 4˚C. The cells pellet was washed twice with PBS then resuspended in FBS with 10% of DMSO and stored at -80˚C.

**RNA extraction from exosomes and bone marrow selected cells**

Total RNA was extracted from previously isolated exosomes using the miRNeasy Micro Kit (Qiagen) then concentrated with the RNA Clean & Concentrator-5 (Zymo). Primary WM cells were obtained from bone marrow biopsy samples using CD19+ microbeads selection (Miltenyi Biotec) as previously described and stored at -80˚C[27]. Cells were homogenized with Qiashredder columns (Qiagen) and RNA was extracted from the homogenized lysate using the miRNeasy Micro Kit (Qiagen). The amount of RNA obtained was measured by fluorimetry with the Quant-iT RiboGreen RNA Assay Kit (Thermo Fisher Scientific).

**Analysis of exosomal microRNA expression**

**TaqMan assay.** MiRNA profiling was performed using TaqMan Array Cards (Thermo Fisher Scientific). A total of 377 mature miRNAs based on miRbase v21 were interrogated on the A v2.1 card for each sample. Reverse transcription (RT) was performed using the TaqMan MicroRNA Reverse Transcription Kit and Megaplex RT Primers, Human Pool A v2.1 (Thermo Fisher Scientific) according to the manufacturer’s protocol, with a starting amount of RNA ranging from 3 to 25 ng. The RT products (4 μL) were pre-amplified in 20 μL reactions with the Megaplex PreAmp Primers Human Pool A v2.1 (10x) and the TaqMan PreAmp Master Mix (2x) (Thermo Fisher Scientific). The amplification was performed at 95˚C for 10 min, 55˚C for 2 min, 72˚C for 2 min, then 16 cycles at 95˚C for 15 seconds, 60˚C for 4 min, followed by 99.9˚C for 10 min, and 4˚C on hold. Undiluted pre-amplification products (1x final concentration) were used to prepare the real-time qPCR samples with 2x TaqMan Master Mix II, no UNG (Thermo Fisher Scientific). All the TaqMan Array Cards were run on the Applied Biosystems 7900HT Fast Real-Time PCR System according to manufacturer’s protocol. All Ct values above 35 cycles were considered as undetectable. We normalized the data with a
universal method for miRNA RT-qPCR data normalization using the mean expression value of all expressed miRNAs in a given sample[28].

**Firefly multiplex circulating miRNA assay.** To exclude any potential confounding effect due to the blood collection method (use of heparin or citrate EDTA-coated tubes) on the assay results, peripheral blood was collected from 6 patients in one tube containing heparin and one tube containing citrate EDTA at the same timepoint. Exosomes were isolated from the plasma of these matched samples as previously described. The Oncology panel of the Firefly Multiplex Circulating miRNA Assay (Abcam) was used to analyze these samples. Samples were scanned on a Guava 8HT flow cytometer (EMD Millipore). The signals measured by flow cytometry were converted into microRNA expression data by the Firefly Analysis Workspace software. The data was normalized with the geNORM algorithm which uses the signal of the three probes with the most stable expression across all samples[29]. The algorithm chose let-7i-5p, miR-103a-3p and miR-20a-5p as normalizer probes.

Furthermore, a custom panel comprised of 33 miRNAs (33-plex) was built to measure the expression levels of these miRNAs with the Firefly Multiplex Circulating miRNA Assay. The assay was performed in exosomes isolated from peripheral blood plasma and cell lines as previously described as well as in RNA from cell lines and bone marrow selected WM cells. Samples were scanned on a BD FACS CANTO II flow cytometer with a HTS unit (BD Biosciences). The signals measured by flow cytometry were converted into microRNA expression data by the Firefly Analysis Workspace software. The data was normalized using the geNORM algorithm[29]. The algorithm chose let-7i-5p, miR-20a-5p and miR-223-3p as normalizer probes.

**Statistical analysis**

The primary outcome of interest was the expression of exosomal miRNA and how it correlates with disease stages in WM. Patients’ characteristics were presented as the median and interquartile range (IQR). Principal component analysis (PCA) was performed to distinguish the miRNA signatures between healthy donors and WM patients. The two-sample t-test was applied to explore the difference of each miRNA between two groups and Benjamini and Hochberg correction was used to attenuate cumulative type I errors in multiple comparisons [30]. Then we compared the mean of each miRNA expression between normal adults and WM patients in different disease status by using one-way analysis of variance (ANOVA). The post-hoc analyses tested the differences and linear trend between groups. All statistical analyses were performed in R (version 3.3.3) and SAS 9.2 software (SAS Institute Inc.).

**Results**

To characterize disease progression from smoldering to symptomatic WM, we first isolated exosomes from plasma samples of healthy donors and patients with WM at progressive stages of the disease. The patient characteristics are included in Tables 1 and 2. Transmission electron microscopy with immunogold labeling for the exosome-specific markers CD63 and CD81 and NanoSight analysis confirmed the presence and the size of the exosomes in our samples (S1 Fig)[7].

We next used the TaqMan Array Human MicroRNA A Cards to identify miRNAs differentially expressed in the circulating exosomes of healthy controls (HC, n = 5) and patients with smoldering WM (AWM, n = 9) or previously untreated symptomatic WM (SWM, n = 7). This assay enables the detection of 377 human miRNAs by qRT-PCR. We found 47 microRNAs with significantly different levels of expression between the groups (ANOVA test with Benjamini-Hochberg correction, p < 0.05) (S1 Table). The Principle Component Analysis of the assay results showed that patients with SWM can be distinguished from HC based on their
exosomal miRNA levels. In contrast, the miRNA expression profiles of patients with AWM partially overlapped with those of both the HC and SWM groups, indicative of the heterogeneity of this group of MGUS/smoldering WM that is not well defined (Fig 1). Importantly, we observed no correlation between the bone marrow involvement of patients with AWM and the similarity of these patient's microRNA signatures to either the HC group or the SWM group (S2 Table). This suggests that the differences observed are not merely due to a higher number of tumor derived-exosomes in the peripheral blood resulting from a higher BM involvement.

Of note, a number of the plasma samples available for our study were collected in tubes containing heparin, which is known to inhibit PCR amplification. [31] Therefore we chose for further analysis the Firefly Multiplex Circulating miRNA Assay which is not affected by the use of heparin. To validate our choice, we compared the microRNA levels measured by this assay in exosomes isolated from peripheral blood collected from six patients with WM in both heparin and citrate EDTA-coated tubes. There was no difference in the level of miRNAs observed between matching samples (S2 Fig).

We therefore designed a custom panel to measure with this assay the expression of 33 miRNAs that were selected based on the TaqMan assay results and on a review of the literature for microRNAs with a role in WM pathogenesis [32–36] (S3 Table). The 33-plex assay was used to analyze the circulating exosomes of 70 patient samples including 8 HC, 25 patients with AWM and 37 patients with SWM (including previously untreated WM (n = 10), relapsed WM (n = 22) and refractory WM (n = 5)).

A two-sample t-test between successive groups of disease progression revealed 12 microRNAs differentially expressed between the AWM and HC groups (two-sample t-test with Benjamini-Hochberg correction; adjusted $p < 0.05$). Interestingly, none of the microRNAs of the

| Characteristics                  | Total $n = 16$ | Asymptomatic WM $n = 9$ | Symptomatic WM $n = 7$ | $P$ value |
|----------------------------------|---------------|------------------------|-----------------------|-----------|
| Median age, years (IQR)          |               |                       |                       |           |
| $\geq 70$                        | 65 (56–70)    | 68 (56–70)             | 65 (56–66)            | 0.660     |
| $< 70$                           | 4 (25.0)      | 3 (33.3)               | 1 (14.3)              | 0.585     |
| Sex                              |               |                       |                       |           |
| Male                             | 10 (62.5)     | 6 (66.7)               | 4 (57.1)              | 1.000     |
| Female                           | 6 (37.5)      | 3 (33.3)               | 3 (42.9)              |           |
| Light chain                      |               |                       |                       |           |
| Kappa                            | 12 (73.0)     | 8 (88.9)               | 4 (57.1)              | 0.262     |
| Lambda                           | 4 (25.0)      | 1 (11.1)               | 3 (42.9)              |           |
| Family history for WM            | 2 (12.5)      | 1 (11.1)               | 1 (14.3)              | 1.000     |
| Hemoglobin, g/dL                 |               |                       |                       |           |
| Median (IQR)                     | 12.4 (10.8–13.0) | 13.0 (11.8–14.0)   | 11.8 (10.8–12.5)     | 0.078     |
| $\geq 11$                        | 10 (62.5)     | 6 (66.7)               | 4 (57.1)              | 0.559     |
| $\beta$-microglobulin            |               |                       |                       |           |
| Median (IQR)                     | 2.3 (2.2–2.4) | 2.2 (2.2–2.2)          | 2.4 (2.1–3.9)         | 0.467     |
| $\geq 3.0$ mg/dL                 | 1 (6.3)       | 0 (0.0)                | 1 (14.3)              | 1.000     |
| M-spike                          | 1.3 (0.8–2.1) | 1.2 (0.9–1.6)          | 1.4 (0.7–2.5)         | 0.876     |
| % bone marrow involvement        | 25 (18–50)    | 15 (15–20)             | 30 (30–90)            | 0.008     |
| Deceased                         | 0 (0.0)       | 0 (0.0)                | 0 (0.0)               |           |

https://doi.org/10.1371/journal.pone.0204589.t001
panel showed a significant difference of expression between the AWM and the SWM groups and between the SWM and relapsed WM groups. (Fig 2 and S4 Table)

Moreover, a one-way ANOVA with a test for linear trend was performed on the results of the 33-plex assay. This analysis revealed a group of 4 miRNAs with a statistically significant linear trend between their expression levels in circulating exosomes and the stage of WM progression (ANOVA $p < 0.01$ and $p$-for-trend $< 0.005$ adjusted with Benjamini-Hochberg correction). Three of these miRNAs, namely miR-192-5p, miR-21-5p, and mir-320b showed increased expression levels with disease progression while the expression of the remaining one, let-7d, decreased with disease stage (Fig 3 and S4 Table).

Additionally, we analyzed sequential plasma samples at different stages of disease progression for three of our cohort’s patients with the 33-plex assay. The levels of miR-21-5p and miR-192-5p increased with disease progression in 2 out of the 3 patients while a decrease of let-7d and an increase of miR-320b were observed in all 3 patients, consistently with our findings (Fig 4).

Moreover, we sought to assess whether the miRNA content of respectively tumor-derived exosomes and circulating exosomes reflects the miRNA expression profiles of tumor cells. We examined the microRNA expression levels of CD19-selected bone marrow tumor cells and circulating exosomes from matching peripheral blood plasma samples in 6 patients with WM. Samples were analyzed with the 33-plex assay and the mean Pearson correlation coefficient between the exosomal and cellular miRNA levels detected in the six patients’ samples was 0.52 (S3A Fig). Moreover, in two WM cell lines BCWM.1 and MWCL-1, we compared the miRNA expression levels between the cells and the exosomes derived from these cells.[37, 38]

### Table 2. Clinical characteristics of Waldenström Macroglobulinemia patients—Firefly Multiplex circulating miRNA assay.

| Characteristics                | Total $n = 62$ | Asymptomatic $n = 25$ | Symptomatic naive $n = 10$ | Relapsed $n = 27$ | $P$ value |
|-------------------------------|---------------|-----------------------|---------------------------|------------------|-----------|
| Median age, years (IQR)       | 68 (60–72)    | 69 (59–75)            | 71 (64–77)                | 66 (59–70)       | 0.307     |
| $\geq 70$                     | 25 (40.3)     | 12 (48.0)             | 5 (50.0)                  | 8 (29.6)         | 0.319     |
| $< 70$                        | 37 (59.7)     | 13 (52.0)             | 5 (50.0)                  | 19 (70.4)        |           |
| Sex                           |               |                       |                           |                  |           |
| Male                          | 39 (62.9)     | 16 (64.0)             | 5 (50.0)                  | 18 (66.7)        | 0.641     |
| Female                        | 23 (37.1)     | 9 (36.0)              | 5 (50.0)                  | 9 (33.3)         |           |
| Light chain                   |               |                       |                           |                  |           |
| Kappa                         | 44 (71.0)     | 17 (68.0)             | 9 (90.0)                  | 18 (66.7)        | 0.349     |
| Lambda                        | 18 (29.0)     | 8 (32.0)              | 1 (10.0)                  | 9 (33.3)         |           |
| Family history for WM         | 8 (12.9)      | 1 (4.0)               | 1 (10.0)                  | 6 (22.2)         | 0.146     |
| Hemoglobin, g/dL              |               |                       |                           |                  |           |
| Median (IQR)                  | 11.8 (10.8–13.6) | 12.8 (11.8–14.2) | 10.9 (10.4–12.4)         | 11.1 (10.0–12.0) | 0.001     |
| Hemoglobin $\geq 11$          | 42 (67.7)     | 23 (92.0)             | 5 (50.0)                  | 14 (51.9)        | 0.004     |
| β2-microglobulin              |               |                       |                           |                  |           |
| Median (IQR)                  | 2.7 (2.1–4.1) | 2.3 (1.9–2.7)         | 4.2 (2.4–4.8)             | 3.2 (2.4–4.1)    | 0.003     |
| $\geq 3.0$ mg/dL              | 22 (35.5)     | 3 (12.0)              | 5 (50.0)                  | 14 (51.9)        | 0.011     |
| IgM                           | 2390 (1287–3400) | 1937 (1018–2521) | 2065 (1130–2740)         | 3130 (2226–4490) | 0.006     |
| M-spike                       | 1.3 (0.9–1.9) | 1.1 (0.9–1.4)         | 1.3 (0.9–1.9)             | 1.8 (0.9–2.9)    | 0.121     |
| % bone marrow involvement     | 40 (20–70)    | 30 (20–50)            | 45 (20–70)                | 55 (28–80)       | 0.128     |
| Deceased                      | 8 (12.9)      | 1 (4.0)               | 0 (0.0)                   | 7 (25.9)         |           |

IQR, interquartile range

[https://doi.org/10.1371/journal.pone.0204589.t002](https://doi.org/10.1371/journal.pone.0204589.t002)
Pearson correlation coefficient between the miRNA levels of the cellular and exosomal fractions was of 0.81 for BCWM.1 cells and 0.90 for MWCL-1 cells (S3B Fig).

**Discussion**

Exosomes have been shown to mediate many aspects of tumor development and progression such as immune evasion, metastasis and drug resistance and to enable cross-talk between tumor cells and their microenvironment[7–9, 39, 40]. The effect of exosomes on tumorigenesis can occur through their miRNA content[10–14].

Circulating exosomes can be isolated from the peripheral blood of patients, making them an attractive mean to identify molecular markers of disease progression. In our study, we analyzed the microRNA content of exosomes from the plasma of patients at different stages of WM as well as healthy controls for comparison. Our results show that patients with WM can be distinguished from healthy controls based on the microRNA expression levels in their exosomes. Interestingly, patients with asymptomatic WM displayed expression levels of exosomal miRNAs comparable to those of symptomatic untreated patients, indicating that changes in the microRNA content of circulating exosomes occur before WM progresses into a symptomatic state. These intriguing findings suggest that the bone marrow and immune environments might evolve early after WM initiation and even potentially at the MGUS stage. This hypothesis is also supported by the high frequency of the MYD88 L265P mutation observed in patients with IgM MGUS and AWM. [41, 42] It might also indicate that treatment of WM at the asymptomatic stage could be an interesting therapeutic strategy to explore.
Although the number of samples with asymptomatic WM used in this study was small, future larger studies may help define those that may have a miRNA signature that is “normal or MGUS-like” vs. those that show a “symptomatic WM signature” and are likely to progress to symptomatic disease. Potentially, these patients may benefit from early therapeutic interventions before the development of clinically evident end-organ damage.

Most significantly, we identified a group of four miRNAs whose levels of expression correlated significantly with stages of disease progression (ANOVA $p < 0.01$ and $p$-for trend $< 0.05$). The levels of expression of miR-192-5p, miR-320b and miR-21-5p increased with the disease stage whereas the expression of let-7d was downregulated. In addition, sequential samples from 3 patients showed that indeed the level of expression of these miRNAs changes significantly with disease progression, indicating that these 4 miRNA markers could be used to track disease progression. Further studies in larger cohorts are required to confirm this observation.

Interestingly, let-7d and miR-21-5p have defined roles in cancer as a tumor suppressor miRNA and oncogenic miRNA respectively, supporting their biological relevance in our study. The let-7 family of miRNAs are well-known tumor suppressors in several cancer types.
including multiple myeloma, another plasma cell malignancy\cite{43–45}. A recent study by our group identified low levels of let-7b in circulating exosomes as a marker of multiple myeloma progression\cite{25}. Let-7 exerts its tumor suppressor activity by regulating different oncogenes including MYC, RAS and CCND1\cite{46}. Moreover, it is regulated by the RNA-binding protein LIN28 which had shown aberrant expression in cancer\cite{46}. Conversely, miR-21-5p is recognized as a ubiquitous oncogene and is upregulated in most solid tumors and a number of hematological malignancies\cite{47}. miR-21 exerts its activity by regulating numerous aspects of the tumorigenesis process, notably through the regulation of numerous tumor suppressor genes including PTEN, PDCD4 and CDKAP1\cite{47}. Importantly, overexpression of miR-21 has been shown to promote a pre-B malignant lymphoid-like phenotype in mice\cite{48}.

Both tumor promoting and inhibiting effects have been described for miR-192-5p depending on the type of cancer studied\cite{49–53}. The specific role of this miRNA remains to be elucidated in the specific context of WM. In the same way, studies have reported an anti-tumor activity for miR-320b, however it has also been found as upregulated in the peripheral blood of WM patients compared to patients with IgM MGUS or IgM multiple myeloma and healthy donors\cite{36, 54–56}. Moreover, it has been shown that members of the miR-320 family are preferentially sorted into exosomes derived from both healthy and malignant cells\cite{21}.

A study similar to ours was conducted in a cohort of patients with Multiple Myeloma revealed a different set of microRNAs with a prognostic value in this disease\cite{25}. However, one of these miRNAs was let-7b which belongs to the same family of microRNAs than let-7d. Furthermore, another recent study suggests a potential prognostic role for miR-21 serum levels in Multiple Myeloma\cite{57}.

An interesting feature of circulating exosomes is that the study of their content can provide information not only on tumor cells but also on tumor-supportive tissues across the body. Our
results suggest that exosomes secreted by tumor cells have similar miRNA expression profiles to the cells they originate from. As expected, we observed a lower correlation between the miRNA expression levels in tumor cells and circulating exosomes possibly due to the fact that peripheral blood plasma contains exosomes derived from various cell types including tumor cells, microenvironment cells and immune cells. Nevertheless, the differences in miRNA expression signatures observed in circulating exosomes at different disease states can provide valuable information on changes occurring during disease progression in tumor supportive tissues and the immune system.

In conclusion, we profiled exosomes from the peripheral blood of patients with WM at different stages of disease progression. To our knowledge, this is the first study to define the miRNA exosomal content of WM patient samples. Together, our results suggest that changes in the microRNA content of circulating exosomes occur at early stages of disease progression before symptoms appear in patients. This might indicate that changes in tumor cells and their microenvironment occur before WM progresses into a symptomatic state.

Moreover, we identified a small group of miRNAs whose expression correlated with the disease status of patients, notably the known tumor suppressor miRNA let-7d and the oncogene miR-21 as well as miR-192 and miR-320b. Further evaluation of these miRNAs’ specific effect in WM cells could help us gain further insights on the mechanisms underlying WM pathogenesis and reveal their potential role as novel therapeutic targets for this disease.

Supporting information

S1 Fig. Characterization of exosomes isolated from peripheral blood plasma samples. A) Ultracentrifugation method used for isolation of exosomes from peripheral blood plasma samples and cell culture supernatant. B) Imaging of exosomes isolated from peripheral blood plasma by electron microscopy imaging after staining with human anti-CD63 and anti-CD81 antibodies (magnification 30,000x). C) Analysis of particle size in exosomes isolated from peripheral blood plasma of a patient with WM (sample diluted 1:100 in PBS) with a NanoSight NS300 Instrument (Malvern).

(PDF)

S2 Fig. Effect of blood drawing methods on exosomal miRNA expression. Correlation of microRNA expression levels measured by the Abcam Firefly Multiplex circulating miRNA assay (33-plex) in exosomes isolated from matching peripheral blood plasma samples collected in tubes containing citrate EDTA or heparin in 6 patients with WM.

(TIF)

S3 Fig. Correlation of cellular and exosomal microRNA expression. miRNA expression levels were measured with the Firefly Multiplex Circulating miRNA assay (Abcam) in A) patients with relapsed symptomatic WM (CD19-selected bone marrow cells vs. circulated exosomes) and B) WM cell lines (cells vs. cell-derived exosomes).

(TIF)

S1 Table. Significant exosomal miRNAs measured by the TaqMan Array Cards. ANOVA test results (with Benjamini-Hochberg correction) and p-values and p- for trend after Benjamini and Hochberg correction are shown for exosomal miRNA expression levels measured
with the TaqMan Array Cards (Human Pool A v2.1).

**S2 Table. Bone marrow involvement of patients included in the TaqMan Array analysis.** Percentage of bone marrow (BM) infiltration by tumor cells in bone marrow biopsy samples from patients included in the analysis of circulating exosome miRNA expression with the TaqMan Array Cards (Human Pool A v2.1). (N/A: bone marrow infiltration percentage not available)

**S3 Table. microRNA panel of the 33-plex Firefly Multiplex circulating miRNA assay.**

**S4 Table. 33-plex Firefly Multiplex circulating miRNA assay results.** An ANOVA test and two-samples t-test between 2 groups (Asymptomatic WM vs. Healthy controls and Symptomatic naïve WM vs. Asymptomatic WM) were conducted and p-values and p- for trend after Benjamini and Hochberg correction are shown.

**Acknowledgments**

The authors thank Sigitas Verselis (Molecular Diagnostics, Dana-Farber Cancer Institute) for the core service and advice on study methodology he provided as well as Timothy Erps and Elnaz Atabakhsh (Firefly, Abcam).

**Author Contributions**

**Conceptualization:** Juliette M. Bouyssou, Salomon Manier, Antonio Sacco, Katsutoshi Kokubun, Shokichi Tsukamoto, Olivier Hermine, Aldo M. Roccaro, Irene M. Ghobrial, Marzia Capelletti.

**Data curation:** Juliette M. Bouyssou, Mark Bustoros, Romanos Sklavenitis-Pistofidis, Amir Yosef, Adriana Perilla Glen, Daisy Huynh.

**Formal analysis:** Juliette M. Bouyssou, Chia-Jen Liu.

**Funding acquisition:** Irene M. Ghobrial.

**Investigation:** Juliette M. Bouyssou, Yosra Aljawai, Daisy Huynh, Marzia Capelletti.

**Methodology:** Juliette M. Bouyssou, Antonio Sacco, Katsutoshi Kokubun, Shokichi Tsukamoto, Marzia Capelletti.
Resources: Yosra Aljawai, Jorge J. Castillo, Steven P. Treon, Véronique Leblond.

Supervision: Olivier Hermine, Aldo M. Roccaro, Irene M. Ghobrial, Marzia Capelletti.

Validation: Juliette M. Bouyssou.

Writing – original draft: Juliette M. Bouyssou.

Writing – review & editing: Juliette M. Bouyssou, Chia-Jen Liu, Olivier Hermine, Irene M. Ghobrial, Marzia Capelletti.

References

1. Braggio E, Phillipsborn C, Novak A, Hodge L, Ansell S, Fonseca R. Molecular pathogenesis of Waldenström’s macroglobulinemia. Haematologica. 2012; 97(9):1281–90. https://doi.org/10.3324/haematol.2012.068478 PMID: 22773606; PubMed Central PMCID: PMC3436227.

2. Kapoor P, Ansell SM, Fonseca R, Chanan-Khan A, Kyle RA, Kumar SK, et al. Diagnosis and Management of Waldenstrom Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. JAMA Oncol. 2017. https://doi.org/10.1001/jamaoncol.2016.5763 PMID: 28056114.

3. Kasi PM, Ansell SM, Gertz MA. Waldenstrom macroglobulinemia. Clin Adv Hematol Oncol. 2015; 13(1):56–66. PMID: 25679974.

4. Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, et al. MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia. N Engl J Med. 2012; 367(9):826–33. https://doi.org/10.1056/NEJMoa1200710 PMID: 22931316.

5. Roccaro AM, Sacco A, Jimenez C, Maiso P, Moschetta M, Mishima Y, et al. C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. Blood. 2014; 123(26):4120–31. https://doi.org/10.1182/blood-2014-03-564583 PMID: 24711662.

6. Muz B, de la Puente P, Azab F, Ghobrial IM, Azab AK. Hypoxia promotes dissemination and colonization in new bone marrow niches in Waldenstrom macroglobulinemia. Mol Cancer Res. 2015; 13(2):263–72. https://doi.org/10.1158/1541-7786.MCR-14-0159 PMID: 25232031.

7. Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002; 2(8):569–79. https://doi.org/10.1038/nri855 PMID: 12154376.

8. Suchorska WM, Lach MS. The role of exosomes in tumor progression and metastasis (Review). Oncol Rep. 2016; 35(3):1237–44. https://doi.org/10.3892/or.2015.4507 PMID: 26707854.

9. Boyiadzis M, Whiteside TL. The emerging roles of tumor-derived exosomes in hematological malignancies. Leukemia. 2017; 31(6):1259–68. https://doi.org/10.1038/leu.2017.91 PMID: 28321122.

10. Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012; 18(6):883–91. https://doi.org/10.1038/nm.2753 PMID: 22635005; PubMed Central PMCID: PMC3645291.

11. Rana S, Malinowska K, Zoller M. Exosomal tumor microRNA modulates metaplastic organ cells. Neoplasia. 2013; 15(3):281–95. PMID: 23479506; PubMed Central PMCID: PMC3593151.

12. Roccaro AM, Sacco A, Maiso P, Azab AK, Tai YT, Reagan M, et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest. 2013; 123(4):1542–55. https://doi.org/10.1172/JCI66517 PMID: 23454749; PubMed Central PMCID: PMC3613927.

13. Melo SA, Sugimoto H, O’Connell JT, Kato N, Villanueva A, Vidal A, et al. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell. 2014; 26(5):707–21. https://doi.org/10.1016/j.ccell.2014.09.005 PMID: 25446899; PubMed Central PMCID: PMC4254633.

14. Fong MY, Zhou W, Liu L, Alontaga AY, Chandra M, Ashby J, et al. Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat Cell Biol. 2015; 17(2):183–94. https://doi.org/10.1038/ncb3094 PMID: 25621950; PubMed Central PMCID: PMC4380143.

15. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281–97. PMID: 14744438.

16. Fang Z, Rajewsky N. The impact of miRNA target sites in coding sequences and in 3’UTRs. PLoS One. 2011; 6(3):e18067. Epub 2011/03/30. https://doi.org/10.1371/journal.pone.0018067 PMID: 21445367; PubMed Central PMCID: PMC3062573.
17. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6(11):857–66. https://doi.org/10.1038/nrc1997 PMID: 17060945.

18. Osada H, Takahashi T. MicroRNAs in biological processes and carcinogenesis. Carcinogenesis. 2007; 28(1):2–12. https://doi.org/10.1093/carcin/bgl185 PMID: 17028302.

19. Bouyssou JM, Manier S, Huynh D, Issa S, Roccaro AM, Ghobrial IM. Regulation of microRNAs in cancer metastasis. Biochim Biophys Acta. 2014; 1845(2):255–65. https://doi.org/10.1016/j.bbcan.2014.02.002 PMID: 24569228; PubMed Central PMCID: PMC4170185.

20. Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Ann Rev Pathol. 2014; 9:287–314. https://doi.org/10.1146/annurev-pathol-012513-104715 PMID: 24079833; PubMed Central PMCID: PMC4009396.

21. Zhang J, Li S, Li L, Guo C, Yao J, et al. Exosome and exosomal microRNA: trafficking, sorting, and function. Genomics Proteomics Bioinformatics. 2015; 13(1):17–24. https://doi.org/10.1016/j.gpb.2015.02.001 PMID: 24572432; PubMed Central PMCID: PMC4411500.

22. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008; 110(1):13–21. Epub 2008/07/01. https://doi.org/10.1016/j.ygyno.2008.04.033 PMID: 18589210.

23. Manier S, Liu CJ, Avet-Loiseau H, Park J, Shi J, Campigotto F, et al. Prognostic role of circulating exosomal miRNAs in multiple myeloma. Blood. 2014; 123(2):275–81. Epub 2014/02/01. https://doi.org/10.1182/blood-2013-08-542516 PMID: 24569228; PubMed Central PMCID: PMC4170185.

24. Leleu X, Jia X, Runnels J, Ngo HT, Moreau AS, Farag M, et al. The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood. 2007; 110(13):4417–26. https://doi.org/10.1182/blood-2007-05-092098 PMID: 17761832; PubMed Central PMCID: PMC2234792.

25. Westermark B, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F, et al. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol. 2009; 3(7):RESEARCH0034. PMID: 12184808; PubMed Central PMCID: PMC1734963.

26. Satsangi J, Jewell DP, Welsh K, Bunce M, Bell JI. Effect of heparin on polymerase chain reaction. Lancet. 1994; 343(8911):1509–10. PMID: 7911219.

27. Roccaro AM, Sacco A, Chen C, Runnels J, Leleu X, Azab F, et al. MicroRNA expression in the biology, prognosis, and therapy of Waldenstrom macroglobulinemia. Blood. 2009; 113(18):4391–402. https://doi.org/10.1182/blood-2008-09-178228 PMID: 19074725; PubMed Central PMCID: PMC2843754.

28. Hodge LS, Elsawa SF, Grote DM, Price-Troska TL, Asmann YW, Fonseca R, et al. MicroRNA expression in tumor cells from Waldenstrom’s macroglobulinemia reflects both their normal and malignant cell counterparts. Blood Cancer J. 2011; 1(6):e24. Epub 2012/07/26. https://doi.org/10.1038/bjc.2011.25 PMID: 22829168; PubMed Central PMCID: PMC3255267.

29. Sacco A, Issa GC, Zhang Y, Liu Y, Maiso P, Ghobrial IM, et al. Epigenetic modifications as key regulators of Waldenstrom’s Macroglobulinemia biology. J Hematol Oncol. 2010; 3:38. Epub 2010/10/12. https://doi.org/10.1186/1756-8722-3-38 PMID: 20929526; PubMed Central PMCID: PMC2964547.
36. Kubiczkova Besse L, Sediarikova L, Kryukov F, Nekvindova J, Radova L, Almasi M, et al. Combination of serum microRNA-320a and microRNA-320b as a marker for Waldenstrom macroglobulinemia. Am J Hematol. 2015; 90(3):E51–2. https://doi.org/10.1002/ajh.23910 PMID: 25428891.

37. Ditzel Santos D, Ho AW, Tournilhac O, Hatjiharissi E, Leleu X, Xu L, et al. Establishment of BCWM.1 cell line for Waldenstrom’s macroglobulinemia with productive in vivo engraftment in SCID-hu mice. Exp Hematol. 2007; 35(9):1366–75. Epub 2007/09/01. https://doi.org/10.1016/j.exphem.2007.05.022 PMID: 17761288.

38. Hodge LS, Novak AJ, Grote DM, Braggio E, Ketterling RP, Manske MK, et al. Establishment and characterization of a novel Waldenstrom macroglobulinemia cell line, MWCL-1. Blood. 2011; 117(19):e190–7. https://doi.org/10.1182/blood-2010-12-326868 PMID: 21452686.

39. Zhao L, Liu W, Xiao J, Cao B. The role of exosomes and “exosomal shuttle microRNA” in tumorigenesis and drug resistance. Cancer Lett. 2015; 356(2 Pt B):339–46. https://doi.org/10.1016/j.canlet.2014.10.027 PMID: 25449429.

40. Hui L, Chen Y. Tumor microenvironment: Sanctuary of the devil. Cancer Lett. 2015; 368(1):7–13. https://doi.org/10.1016/j.canlet.2015.07.039 PMID: 26276713.

41. Varettoni M, Arcaini L, Zibellini S, Boveri E, Rattotti S, Riboni R, et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom’s macroglobulinemia and related lymphoid neoplasms. Blood. 2013; 121(13):2522–8. Epub 2013/01/29. https://doi.org/10.1182/blood-2012-09-457101 PMID: 23355535.

42. Correa JG, Cibeira MT, Tovar N, Isola I, Pedrosa F, Diaz T, et al. Prevalence and prognosis implication of MYD88 L265P mutation in IgM monoclonal gammopathy of undetermined significance and smoldering Waldenstrom macroglobulinemia. Br J Haematol. 2017; 179(5):849–51. Epub 2016/09/09. https://doi.org/10.1111/bjh.14266 PMID: 27605200.

43. Roush S, Slack FJ. The let-7 family of microRNAs. Trends Cell Biol. 2008; 18(10):505–16. https://doi.org/10.1016/j.tcb.2008.07.007 PMID: 18774294.

44. Wang T, Wang G, Hao D, Liu X, Wang D, Ning N, et al. Aberrant regulation of the LIN28A/LIN28B and let-7 loop in human malignant tumors and its effects on the hallmarks of cancer. Mol Cancer. 2015; 14:125. https://doi.org/10.1186/s12943-015-0402-5 PMID: 26123544; PubMed Central PMCID: PMCPMC4512107.

45. Pfeffer SR, Yang CH, Pfeffer LM. The Role of miR-21 in Cancer. Drug Dev Res. 2015; 76(6):270–7. https://doi.org/10.1002/ddr.21257 PMID: 26082192.

46. Medina PP, Nolde M, Slack FJ. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature. 2010; 467(7311):86–90. https://doi.org/10.1038/nature09284 PMID: 20693987.

47. Xu YJ, Fan Y. MiR-215/192 participates in gastric cancer progression. Clin Transl Oncol. 2015; 17(1):34–40. https://doi.org/10.1007/s12094-014-1194-6 PMID: 24981590.

48. Lian J, Jing Y, Dong Q, Huan L, Chen D, Bao C, et al. miR-192, a prognostic indicator, targets the SLC39A6/SNAIL pathway to reduce tumor metastasis in human hepatocellular carcinoma. Oncotarget. 2016; 7(3):2672–83. https://doi.org/10.18632/oncotarget.6603 PMID: 26684241; PubMed Central PMCID: PMCPMC4823063.

49. Wu SY, Rupaimoole R, Shen F, Pradeep S, Pecot CV, Ivan C, et al. A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. Nat Commun. 2016; 7:2672–83. https://doi.org/10.1038/ncomms11169 PMID: 27041221; PubMed Central PMCID: PMCPMC4823063.

50. Sasaki CT, Vageli DP. miR-21, miR-155, miR-192, and miR-375 Deregulations Related to NF-kappaB Activation in Gastrroduodenal Fluid-Induced Early Preneoplastic Lesions of Laryngeal Mucosa In Vivo. Neoplasia. 2016; 18(6):329–38. https://doi.org/10.1016/j.neo.2016.04.007 PMID: 27292022; PubMed Central PMCID: PMCPMC4823063.

51. Wang H, Cao F, Li X, Miao H, E J, Xing J, et al. miR-320b suppresses cell proliferation by targeting c-Myc in human colorectal cancer cells. BMC Cancer. 2015; 15:748. https://doi.org/10.1186/s12885-015-1728-5 PMID: 26487644; PubMed Central PMCID: PMCPMC4617986.
55. Li Y, Tang X, He Q, Yang X, Ren X, Wen X, et al. Overexpression of Mitochondria Mediator Gene TRIAP1 by miR-320b Loss Is Associated with Progression in Nasopharyngeal Carcinoma. PLoS Genet. 2016; 12(7):e1006183. https://doi.org/10.1371/journal.pgen.1006183 PMID: 27428374; PubMed Central PMCID: PMCPMC4948882.

56. Lv GY, Miao J, Zhang XL. Long Non-Coding RNA XIST Promotes Osteosarcoma Progression by Targeting Ras-Related Protein RAP2B via miR-320b. Oncol Res. 2017. https://doi.org/10.3727/096504017X14920318811721 PMID: 28409547.

57. Wang JH, Zhou WW, Liu BX, Man DL, Yang ZD, Liu FR, et al. Expression and significance of miR-21 in multiple myeloma patients. Genet Mol Res. 2016; 15(1). Epub 2016/02/26. https://doi.org/10.4238/gmr.15016892 PMID: 26909911.